Show simple item record

dc.contributor.authorPowles, T. B.
dc.contributor.authorRodriguez-Vida, A.
dc.contributor.authorMamtani, R.
dc.contributor.authorYu, E. Y.
dc.contributor.authorNam, K.
dc.contributor.authorImai, K.
dc.contributor.authorMoreno, B. H.
dc.contributor.authorAlva, A.
dc.contributor.authorCsoszi, T.
dc.contributor.authorÖZGÜROĞLU, Mustafa
dc.contributor.authorMatsubara, N.
dc.contributor.authorGeczi, L.
dc.contributor.authorCheng, S. Y-S.
dc.contributor.authorFradet, Y.
dc.contributor.authorOudard, S.
dc.contributor.authorVulsteke, C.
dc.contributor.authorMorales Barrera, R.
dc.contributor.authorFlechon, A.
dc.contributor.authorGunduz, S.
dc.contributor.authorLoriot, Y.
dc.date.accessioned2021-03-02T17:07:05Z
dc.date.available2021-03-02T17:07:05Z
dc.identifier.citationAlva A., Csoszi T., ÖZGÜROĞLU M., Matsubara N., Geczi L., Cheng S. Y. , Fradet Y., Oudard S., Vulsteke C., Morales Barrera R., et al., "Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361", ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31
dc.identifier.othervv_1032021
dc.identifier.otherav_80f1a381-0806-47a4-bd14-64b339fdefa2
dc.identifier.urihttp://hdl.handle.net/20.500.12627/3573
dc.identifier.urihttps://doi.org/10.1016/j.annonc.2020.08.2252
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectONKOLOJİ
dc.titlePembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361
dc.typeBildiri
dc.contributor.departmentUniversity of Michigan System , ,
dc.identifier.volume31
dc.contributor.firstauthorID2286967


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record